Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
Article Abstract:
The objective is to assess the efficacy and safety of 24 or 28 weeks of treatment with a low or standard dose of ribavirin. It is concluded that the treatment with peginterferon-alpha2a and ribavirin is individualized by genotype and patients with hepatitis C virus (HCV) genotype 1 require treatment for 48 weeks and standard dose of ribavirin and those with HCV genotype 2 and 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Heterogeneous virologic response rates to interferon-based therapy in patients with chronic Hepatitis C: who responds less well?
Article Abstract:
The introduction of new agents and regimes for the treatment of chronic hepatitis C, such as pegylated interferons and combination therapy with ribavirin, has resulted in substantial improvements in sustained virologic response rates. The data on interferon-based therapies among patients with lower chances for sustained virologic response and the potential of the new pegylated interferons is reviewed and discussed.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
Article Abstract:
Chronic Hepatitis B is associated with serious complications including liver failure, cirrhosis and hepatocellular carcinoma. Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
- Abstracts: Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial
- Abstracts: Epilepsy and pregnancy: an obstetric perspective. Cohort study of forceps delivery and risk of epilepsy in adulthood
- Abstracts: Pregnancy complicated by congenital hepatic fibrosis with cavernous transformation of the portal vein: a case report
- Abstracts: The interval between pregnancies and the outcome of subsequent births. Small-for-gestational-age infants and risk of fetal death in subsequent pregnancies